Malin stock

MLC · Euronext Dublin · EUR

€6.00Change from previous close: +0.84%Absolute change: +€0.05

Close · November 13, 2026

Price history

−27.71% over the period

1 year: from €8.30 (November 13, 2025) to €6.00 (November 13, 2026), −27.71%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026€6.00
October 30, 2026€5.95
September 30, 2026€7.00
August 31, 2026€7.00
July 31, 2026€7.10
June 30, 2026€7.45
May 29, 2026€7.75
April 30, 2026€7.95
March 31, 2026€7.70
February 27, 2026€7.60
January 30, 2026€8.00
December 31, 2025€7.70
November 28, 2025€7.85
November 13, 2025€8.30

At a glance

  • The company

    Investment company focusing on life sciences and healthcare companies across oncology, immunology, and genetic diseases

  • Latest results

    Quarter to December 31, 2025 · EPS -€0.05

TickerLandia's take on Malin

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€5.95
52-wk high€9.30

−35.48% from the 52-week high

Analysts · 1 analyst

Average target€15.50+158.33% vs. price

Buy 1 · Hold 0 · Sell 0

TickerLandia Fingerprint: Malin

Compared with similar companies: very low profitability and very weak momentum.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

3 dimensions without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Malin is cheaper than similar companies

Malin's Price/book: 0.67, −77% against the median of a group of 11 similar companies (2.91).

Compared with 11 similar companies

Malin's metrics compared with similar companies
MetricMalinPosition in the groupBand
Operating margin0.0%Low
ROE-6.0%Low
Price/book0.67Low
Net margin0.0%Low
Gross margin0.0%Low

Grey band: the middle half of the group; tick: the median; dot: Malin. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Net income

-€200K

Latest quarter · Q4 2025

Numbers and valuation

Full valuation
Market cap
€25.96M
EPS
€0.00
Volume
10
Daily trading
€2.18K
Dividend yield
0.00%

How Malin is changing

All results
  • Shares outstanding down 83.8% in 5 years

  • Profitable in 2 of 5 fiscal years

Returns

Malin returns

€1,000 invested in Malin 5 years ago, on November 15, 2021, would be worth €896 today: −10.45% in total, −2.19% per year. This is the price return only: dividends are excluded.

PeriodMalin€1,000 becomes
1 month−13.67%€863
6 months−25.00%€750
Year to date−22.08%€779
1 year−27.71%€723
3 years+50.00%€1,500
5 years−10.45%€896
10 years−50.12%€499

Price only, without dividends. Calculate your investment

The chart in detail

Malin: technical analysis

Malin is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 61.0% below its all-time closing high (€15.36, June 30, 2016).

Trend
Downward
RSI (14 sessions)
15
Below 30: a strong fall in a short time
vs 200-session average
−17.68%

Active signals

  • RSI below 30: the stock has fallen a lot in a short time.

    since October 22, 2026

Support and resistance

Price areas where Malin has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€7.12+18.59%13 touches, last on August 4, 2026
  2. Resistance€7.00+16.59%65 touches, last on October 21, 2026
  3. Resistance€6.80+13.33%3 touches, last on September 21, 2026
  4. Last price€6.00
  5. Support€5.95−0.83%8 touches, last on November 6, 2026

Volatility and risk

Volatility (60 sessions, annualised)
24.2%
Largest fall in the last year
−28.31%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Malin: seasonality

Average monthly price change over 13 years

+3.9%Jan+1.0%Feb−2.2%Mar−3.0%Apr−0.7%May+3.2%Jun−1.9%Jul−4.2%Aug+3.6%Sep−5.0%Oct+7.8%Nov+2.2%Dec

Over the last 13 years, the strongest month for Malin has been November: +7.84% on average, positive in 9 years out of 12. The weakest has been October: −5.05% on average, positive in 2 years out of 13.

Show chart data
MonthAverageMedianPositive years
January+3.88%+4.30%8 of 12
February+1.02%−1.23%3 of 12
March−2.21%+0.66%6 of 12
April−3.02%−1.34%5 of 13
May−0.71%0.00%5 of 13
June+3.23%0.00%6 of 13
July−1.88%0.00%5 of 13
August−4.18%−0.71%4 of 13
September+3.60%−0.87%2 of 13
October−5.05%−6.96%2 of 13
November+7.84%+6.01%9 of 12
December+2.17%−0.41%5 of 12

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Malin and its competitors

Europe and North America are the markets in which Malin Corporation plc operates as an investment company, together with its subsidiaries. The group invests in life sciences and healthcare companies, with a focus on therapeutic areas such as oncology, immunology and genetic diseases. Its holdings are therefore tied to businesses working in these fields across the two regions.

Headquarters
Dublin, Ireland
Employees
2
Founded
2014
Chief executive
Fiona Dunlevy
Malin and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
MalinMLC$28.69M0.0%—−25.00%
EvotecEVT$582.49M-18.0%—−35.51%
PharmaNutraPHN$880.46M21.7%35.0−6.12%
Faes FarmaFAE$1.74B13.0%18.7+10.55%
FagronFAGR$1.96B14.3%19.4−0.21%
AlmirallALM$2.57B13.3%32.4−5.83%

Same industry or related industries, similar size. Compare Malin with its competitors · Full profile